Treatment Advances in Metastatic CRPC

Video

For High-Definition, Click

Raoul Concepcion, MD, leads the discussion on recent advances in treatment for mCRPC, including checkpoint inhibitors and novel hormonal agents. Neal Shore, MD, explains that checkpoints are in place to regulate T-cell activity and checkpoint inhibitors work by turning off these checkpoints and activating T cells.

Immunotherapies focus on addressing the patient’s immune system rather than directly treating the cancer itself, remarks Phillippa Cheetham, MD. Immunotherapy may play an especially important role in the treatment of patients with more aggressive disease.

Advances have also been made with regard to antiandrogens. Hormonal agents in development include ARN-509, ODM-201, and galeterone. Oliver Sartor, MD, comments that it is a very exciting time in terms of hormonal therapy and immunotherapy, and trial data will clarify the roles of each of these agents in the treatment of mCRPC.

Related Videos
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Minesh Mehta, MD
Wenxin (Vincent) Xu, MD,
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD